Clinical trials: Acquired Immune Deficiency Syndrome Virus
Human Immunodeficiency Virus
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents.
- Trial name
- NCT00791700
- Testing
- Maraviroc
- Where
- 41 sites in United States, Brazil and 7 more
- Volunteers
- 103 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease
To determine the toxicity of low dose foscarnet administered for 4 weeks to HIV infected patients who are asymptomatic, have AIDS, or other HIV associated conditions and a CD4+ lymphocyte count < 500 cells/mm3.
- Trial name
- NCT00000729
- Testing
- Foscarnet sodium
- Where
- 11 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
To evaluate the safety and tolerability of multiple escalating doses of 1263W94 administered orally for 28 days in HIV infected patients with asymptomatic CMV shedding.
- Trial name
- NCT00002373
- Testing
- Maribavir
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Glaxo Wellcome
Alcoholism, HIV Infection
Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
We propose to test, by DNA linkage analysis of family pedigree members, the following interrelated hypotheses: 1) that sexual orientation is genetically influenced; 2) that the development of Kaposi's sarcoma and other outcomes…
- Conditions
- Alcoholism, HIV Infection, Homosexuality, Kaposi's Sarcoma
- Trial name
- NCT00001294
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Human Immunodeficiency Virus
Evaluation of Problem Management Plus in Pregnant Women With HIV in Kenya
This study includes secondary quantitative analysis, qualitative methods, and hybrid type 2 implementation-effectiveness pilot trial.
- Trial name
- Tatua (NCT05841797)
- Testing
- In-Person Program Management Plus (PM+), Mobile Program Management Plus (mHealth PM+)
- Where
- Kenya
- Volunteers
- 120 people
- Sponsor
- University of Colorado, Denver
AIDS, Pneumonia
Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia
Screening for risk factors related to lung function impairment in patients who have recovered from AIDS with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this…
- Trial name
- NCT06137196
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangzhou 8th People's Hospital
Herpes Simplex, HIV Infections
Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)
To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303 gel in combination with acyclovir, relative to acyclovir alone, for the treatment of recurrent Herpes Simplex Virus (HSV) 1 and 2…
- Trial name
- NCT00002186
- Testing
- Crofelemer, Acyclovir
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 400 people
- Sponsor
- Shaman Pharmaceuticals
Human Immunodeficiency Virus
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy who are virological suppressed (HIV-1 < 50 copies/mL
- Trial name
- Sound (NCT04826562)
- Testing
- Dolutegravir/Lamivudine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Saint Michael's Medical Center
Hiv
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good…
- Trial name
- NCT05001373
- Testing
- Core-g28v2 60mer mRNA Vaccine, eOD-GT8 60mer mRNA Vaccine
- Where
- 4 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Sarcoma, Kaposi, Lymphoma, Non-Hodgkin
A Study of Patients With AIDS Syndrome
The purpose of this study is to find out why cancers develop in HIV-positive patients. Cancer is a leading cause of death in AIDS patients.
- Conditions
- Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, AIDS-Related
- Trial name
- NCT00001120
- Where
- 23 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
This study will evaluate the safety, pharmacokinetics and efficacy of the CCR5 antagonist INCB009471 in HIV-1 infected patients who are antiretroviral therapy naïve, or who are not currently on a HAART regimen and have not…
- Trial name
- NCT00393120
- Testing
- INCB009471
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Incyte Corporation
Infection, Human Immunodeficiency Virus
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus…
- Trial name
- NCT00950859
- Testing
- GSK1349572 (Cohort I), GSK1349572 (Cohort II)
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 51 people
- Sponsor
- ViiV Healthcare
Hiv
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
The purpose of this study is to assess the effectiveness of the FPI bundled implementation strategy in increasing HIV testing, Pre-exposure prophylaxis (PrEP) linkage (e.g., prescription) and knowledge, and condom use/access.
- Trial name
- FPI (NCT06062342)
- Testing
- FPI
- Where
- United States
- Volunteers
- 20,400 people, healthy volunteers welcome
- Sponsor
- University of Miami
HIV Infections
Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)
This study will test the safety and immunogenicity of an investigational Human Immunodeficiency Virus (HIV) vaccine. Immunogenicity will be measured by evaluating the immune response to several different dose levels.
- Trial name
- NCT00350623
- Testing
- MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Mental Health
Digital Star: HIV Prevention for Youth in Mental Health Treatment
Teenagers in mental health treatment are at greater risk for HIV and other sexually transmitted infections. This greater risk comes from many factors, some of which are related to poor emotion regulation and low self-confidence.
- Trial name
- DSTAR (NCT02921841)
- Testing
- D*STAR, D*HEALTH
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Rhode Island Hospital
HIV/AIDS
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression…
- Trial name
- NCT04819347
- Testing
- Albuvirtide, 3BNC117
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Frontier Biotechnologies Inc.
Hiv
Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV
Prospective, multicenter study to evaluate tolerability, adherence and efficacy of a 28-day course of TAF/FTC/RPV, an HIV post-exposure prophylaxis after a potential sexual or blood exposure to HIV.
- Trial name
- AES ODEFSEY (NCT03451032)
- Testing
- Non Interventional Study
- Where
- 6 sites in France
- Volunteers
- 150 people
- Sponsor
- Nantes University Hospital
HIV-infection
Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500
A randomized single dose, drug-drug interaction study in healthy volunteers for VM - 1500 given alone or in combination with Raltegravir or Darunavir in a 3 arm approach.
- Trial name
- NCT02489487
- Testing
- VM-1500, Darunavir, Ritonavir
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Viriom
Human Immunodeficiency Virus (HIV), Mitochondrial Diseases
Mitochondria in HIV and Aging (MITO+)
Older adults with human immunodeficiency virus (HIV) and a long history of antiretroviral therapy have more mitochondrial dysfunction- the cells that help them make energy.
- Trial name
- (MITO+) (NCT03489421)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
HIV related cognitive impairment still occurs despite highly active antiretroviral therapy (HAART). HIV disease affects the brain in 20-40% of patients with advancing HIV disease; leading to varying degrees of cognitive…
- Trial name
- HANDmac (NCT01449006)
- Testing
- Maraviroc
- Where
- 2 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Bruce Brew
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.